• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Castleman Disease Collaborative Network, Janssen partner on study

Castleman Disease Collaborative Network, Janssen partner on study

April 12, 2017
CenterWatch Staff

The Castleman Disease Collaborative Network (CDCN), a global nonprofit organization dedicated to accelerating research and treatments for Castleman disease (CD), a rare immunological disease, announced a collaboration with Janssen Research & Development to conduct a proteomics study of idiopathic multicentric Castleman disease (iMCD), a deadly subtype of CD. This collaborative study has the potential to improve diagnosis and treatment for iMCD patients. The collaboration combines CDCN’s strong expertise in iMCD research and its world-wide network of physician researchers with Janssen’s industry leading iMCD research resources.

The causes of iMCD, one of three subtypes of CD, are unknown. About 1,0001new cases of iMCD are diagnosed each year in the United States and approximately 35% of patients die within five years of diagnosis2. iMCD patients experience a wide spectrum of symptoms, from mild flu-like symptoms to acute sepsis-like multiple organ system failure due to uncontrolled immune system activation. Siltuximab, an anti-interleukin-6 monoclonal antibody developed by Janssen, was approved by the FDA for treatment of iMCD in 2014. However, many questions still exist related to iMCD, particularly for patients that do not respond to siltuximab.

“Ever since I was diagnosed with iMCD ten years ago, I have been dedicated to doing whatever I can to improve CD research and awareness. We have made progress, but have important work ahead of us to understand the causes of CD, and develop diagnostic tests and treatments for it,” stated, Greg Pacheco, board president of CDCN.

Recently, CDCN brought together a team of physicians and researchers to establish the first-ever diagnostic criteria for iMCD, which was published last month in the journal, Blood. These criteria include clinical and pathology features, and diseases to exclude. However, the diagnostic process can be time-consuming as there is no definitive test for iMCD. Therefore, the aim of this study is to identify molecules whose levels are specifically altered in the blood of iMCD patients. The hope is that these molecules can be used to shorten the time required to diagnose iMCD for critically ill patients and as therapeutic targets for treatment of iMCD patients that do not respond to current therapies. To accomplish these goals, the collaborators will measure the level of approximately 1,300 analytes in more than 260 serum samples collected from approximately 100 iMCD patients at various time points during active disease.

This unprecedented collaboration reflects a trend towards greater collaboration between industry, research foundations, and academia, as well as continued interest in drug development for rare diseases. Janssen will fund a significant portion of the project and contribute iMCD serum samples that were collected as part of a previous clinical trial. CDCN’s role in the collaboration includes, through its network of physician scientists, partnering with seven academic institutes from around the globe to contribute iMCD, related disease and ‘normal’ serum samples and analyzing the results of the proteomic screen. CDCN will also fund a portion of the project.

“It is unusual and creative for a pharmaceutical company to open up their banks of samples for research and to do it in such a collaborative fashion. Janssen’s commitment to fully leveraging its iMCD resources to advance high-impact, patient-centric research demonstrates its commitment to helping patients,” stated Pacheco. “The results of this ambitious research project have the potential to shed significant light on a poorly understood disease and improve survival for all CD patients.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing